The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Donnelly, J. J.
Right arrow Articles by Liu, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Donnelly, J. J.
Right arrow Articles by Liu, M. A.
The Journal of Immunology, 2005, 175: 633-639.
Copyright © 2005 by The American Association of Immunologists

BRIEF REVIEW

DNA Vaccines: Progress and Challenges1

John J. Donnelly2,*, Britta Wahren{dagger} and Margaret A. Liu{ddagger}

* Chiron Vaccines, Chiron Corporation, Emeryville, CA 94608; {dagger} Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden; and {ddagger} Transgene, SA, Lafayette, CA 94549

In the years following the publication of the initial in vivo demonstration of the ability of plasmid DNA to generate protective immune responses, DNA vaccines have entered into a variety of human clinical trials for vaccines against various infectious diseases and for therapies against cancer, and are in development for therapies against autoimmune diseases and allergy. They also have become a widely used laboratory tool for a variety of applications ranging from proteomics to understanding Ag presentation and cross-priming. Despite their rapid and widespread development and the commonplace usage of the term "DNA vaccines," however, the disappointing potency of the DNA vaccines in humans underscores the challenges encountered in the efforts to translate efficacy in preclinical models into clinical realities. This review will provide a brief background of DNA vaccines including the insights gained about the varied immunological mechanisms that play a role in their ability to generate immune responses.




This article has been cited by other articles:


Home page
 J. Virol.Home page
A.-H. Hovav, M. Santosuosso, M. Bivas-Benita, A. Plair, A. Cheng, M. Elnekave, E. Righi, T. Chen, S. Kashiwagi, M. W. Panas, et al.
X4 Human Immunodeficiency Virus Type 1 gp120 Down-Modulates Expression and Immunogenicity of Codelivered Antigens
J. Virol., November 1, 2009; 83(21): 10941 - 10950.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
C.-H. Pan, G. S. Jimenez, N. Nair, Q. Wei, R. J. Adams, F. P. Polack, A. Rolland, A. Vilalta, and D. E. Griffin
Use of Vaxfectin Adjuvant with DNA Vaccine Encoding the Measles Virus Hemagglutinin and Fusion Proteins Protects Juvenile and Infant Rhesus Macaques against Measles Virus
Clin. Vaccine Immunol., August 1, 2008; 15(8): 1214 - 1221.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
N. Huebener, S. Fest, A. Strandsby, E. Michalsky, R. Preissner, Y. Zeng, G. Gaedicke, and H. N. Lode
A rationally designed tyrosine hydroxylase DNA vaccine induces specific antineuroblastoma immunity
Mol. Cancer Ther., July 1, 2008; 7(7): 2241 - 2251.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. M. Truscott, X. Wang, L. Lybarger, W. E. Biddison, C. McBerry, J. M. Martinko, J. M. Connolly, G. P. Linette, D. H. Fremont, T. H. Hansen, et al.
Human Major Histocompatibility Complex (MHC) Class I Molecules with Disulfide Traps Secure Disease-related Antigenic Peptides and Exclude Competitor Peptides
J. Biol. Chem., March 21, 2008; 283(12): 7480 - 7490.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Gupta, R. Boppana, G. C. Mishra, B. Saha, and D. Mitra
HIV-1 Tat Suppresses gp120-Specific T Cell Response in IL-10-Dependent Manner
J. Immunol., January 1, 2008; 180(1): 79 - 88.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. D. Bins, M. C. Wolkers, M. D. van den Boom, J. B. A. G. Haanen, and T. N. M. Schumacher
In Vivo Antigen Stability Affects DNA Vaccine Immunogenicity
J. Immunol., August 15, 2007; 179(4): 2126 - 2133.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Stoecklinger, I. Grieshuber, S. Scheiblhofer, R. Weiss, U. Ritter, A. Kissenpfennig, B. Malissen, N. Romani, F. Koch, F. Ferreira, et al.
Epidermal Langerhans Cells Are Dispensable for Humoral and Cell-Mediated Immunity Elicited by Gene Gun Immunization
J. Immunol., July 15, 2007; 179(2): 886 - 893.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
W. Mwangi, W. C. Brown, G. A. Splitter, C. J. Davies, C. J. Howard, J. C. Hope, Y. Aida, Y. Zhuang, B. J. Hunter, and G. H. Palmer
DNA Vaccine Construct Incorporating Intercellular Trafficking and Intracellular Targeting Motifs Effectively Primes and Induces Memory B- and T-Cell Responses in Outbred Animals
Clin. Vaccine Immunol., March 1, 2007; 14(3): 304 - 311.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
Y. Yue, A. Kaur, M. K. Eberhardt, N. Kassis, S. S. Zhou, A. F. Tarantal, and P. A. Barry
Immunogenicity and Protective Efficacy of DNA Vaccines Expressing Rhesus Cytomegalovirus Glycoprotein B, Phosphoprotein 65-2, and Viral Interleukin-10 in Rhesus Macaques
J. Virol., February 1, 2007; 81(3): 1095 - 1109.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
J. Wang, S. A. Gujar, L. Cova, and T. I. Michalak
Bicistronic Woodchuck Hepatitis Virus Core and Gamma Interferon DNA Vaccine Can Protect from Hepatitis but Does Not Elicit Sterilizing Antiviral Immunity
J. Virol., January 15, 2007; 81(2): 903 - 916.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
M. Breton, C. Zhao, M. Ouellette, M. J. Tremblay, and B. Papadopoulou
A recombinant non-pathogenic Leishmania vaccine expressing human immunodeficiency virus 1 (HIV-1) Gag elicits cell-mediated immunity in mice and decreases HIV-1 replication in human tonsillar tissue following exposure to HIV-1 infection
J. Gen. Virol., January 1, 2007; 88(1): 217 - 225.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
K. Moll, F. Pettersson, A. M. Vogt, C. Jonsson, N. Rasti, S. Ahuja, M. Spangberg, O. Mercereau-Puijalon, D. E. Arnot, M. Wahlgren, et al.
Generation of Cross-Protective Antibodies against Plasmodium falciparum Sequestration by Immunization with an Erythrocyte Membrane Protein 1-Duffy Binding-Like 1{alpha} Domain
Infect. Immun., January 1, 2007; 75(1): 211 - 219.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
O. Hamid, J. C. Solomon, R. Scotland, M. Garcia, S. Sian, W. Ye, S. L. Groshen, and J. S. Weber
Alum with Interleukin-12 Augments Immunity to a Melanoma Peptide Vaccine: Correlation with Time to Relapse in Patients with Resected High-Risk Disease
Clin. Cancer Res., January 1, 2007; 13(1): 215 - 222.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
V. C. Huber, R. M. McKeon, M. N. Brackin, L. A. Miller, R. Keating, S. A. Brown, N. Makarova, D. R. Perez, G. H. MacDonald, and J. A. McCullers
Distinct Contributions of Vaccine-Induced Immunoglobulin G1 (IgG1) and IgG2a Antibodies to Protective Immunity against Influenza.
Clin. Vaccine Immunol., September 1, 2006; 13(9): 981 - 990.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
E. M. Bublil, S. Yeger-Azuz, and J. M. Gershoni
Computational prediction of the cross-reactive neutralizing epitope corresponding to the monoclonal antibody b12 specific for HIV-1 gp120
FASEB J, September 1, 2006; 20(11): 1762 - 1774.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. Bolesta, A. Kowalczyk, A. Wierzbicki, C. Eppolito, Y. Kaneko, M. Takiguchi, L. Stamatatos, P. A. Shrikant, and D. Kozbor
Increased Level and Longevity of Protective Immune Responses Induced by DNA Vaccine Expressing the HIV-1 Env Glycoprotein when Combined with IL-21 and IL-15 Gene Delivery
J. Immunol., July 1, 2006; 177(1): 177 - 191.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
U. Wille-Reece, B. J. Flynn, K. Lore, R. A. Koup, A. P. Miles, A. Saul, R. M. Kedl, J. J. Mattapallil, W. R. Weiss, M. Roederer, et al.
Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates
J. Exp. Med., May 15, 2006; 203(5): 1249 - 1258.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
C. Trumpfheller, J. S. Finke, C. B. Lopez, T. M. Moran, B. Moltedo, H. Soares, Y. Huang, S. J. Schlesinger, C. G. Park, M. C. Nussenzweig, et al.
Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine
J. Exp. Med., March 20, 2006; 203(3): 607 - 617.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
G. W. Stone, S. Barzee, V. Snarsky, K. Kee, C. A. Spina, X.-F. Yu, and R. S. Kornbluth
Multimeric Soluble CD40 Ligand and GITR Ligand as Adjuvants for Human Immunodeficiency Virus DNA Vaccines
J. Virol., February 15, 2006; 80(4): 1762 - 1772.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.